101648/196: A Long-Term, Open-Label Continuation Study of Once Daily Administration of Ropinirole CR Tablets to Patients With Parkinson's Disease Who Completed the Previous Ropinirole CR Studies 167 or 164
Phase of Trial: Phase III
Latest Information Update: 04 Jun 2015
At a glance
- Drugs Ropinirole (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors GlaxoSmithKline
- 28 Apr 2010 Actual end date (Mar 2009) added as reported by ClinicalTrials.gov.
- 28 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2010 Trial phase changed from II to III as reported by ClinicalTrials.gov.